Skip to main content
驱动力 logo

驱动力 — Investor Relations & Filings

Ticker · 920275 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 479 across all filing types
Latest filing 2024-05-20 Declaration of Voting R…
Country CN China
Listing Beijing Stock Exchange 920275

About 驱动力

https://www.chinaedrive.com/

Drive Power Bio-tech specializes in the research, development, and manufacturing of functional additives designed for animal nutrition. The company focuses on hematopoietic technology, providing solutions that enhance hemoglobin synthesis, strengthen immune responses, and support intestinal health. Its product portfolio includes specialized nutritional supplements that optimize metabolic processes and improve growth performance. By leveraging biotechnological innovation, the company develops high-efficiency additives aimed at enhancing physiological health and production efficiency in large-scale agricultural environments.

Recent filings

Filing Released Lang Actions
2023年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a "2023 Annual General Meeting Resolution Announcement" for Guangdong Driving Force Biotechnology Group Co., Ltd. It details the meeting date, attendance, agenda items, and voting results for various proposals including the 2023 annual board work report, supervisory board report, financial statements, annual report approval, profit distribution plan, remuneration plans, and other related matters. The document is a formal announcement of the resolutions passed at the Annual General Meeting (AGM) rather than the full annual report or financial statements themselves. It references other documents (e.g., the 2023 Annual Report) that are disclosed elsewhere. The length is about 4409 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-05-20 Chinese
北京市中伦（广州）律师事务所关于广东驱动力生物科技集团股份有限公司2023年年度股东大会的法律意见书
Regulatory Filings
2024-05-20 Chinese
大华会计师事务所（特殊普通合伙）关于对广东驱动力生物科技集团股份有限公司问询函的回复
Regulatory Filings
2024-05-12 Chinese
关于对北京证券交易所问询函回复的公告
Regulatory Filings Classification · 95% confidence The document is a detailed response to an inquiry letter from the Beijing Stock Exchange's Listing Company Management Department regarding the company's business operations, revenue recognition policies, accounting corrections, and internal controls. It includes extensive financial data adjustments, explanations of accounting treatments, and internal control measures. The document addresses corrections to previously issued financial statements for multiple periods, including annual and quarterly reports, and discusses the company's compliance with accounting standards and internal controls. It is not a full annual or interim report itself but a regulatory disclosure responding to a regulatory inquiry, providing clarifications and corrections. The document is lengthy (9693 characters) and contains detailed explanations and financial data but is primarily a regulatory response rather than a standalone financial report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2024-05-12 Chinese
投资者关系活动记录表
Earnings Release Classification · 90% confidence The document is titled as an "投资者关系活动记录表" which translates to "Investor Relations Activity Record". It details a performance explanation meeting held on May 13, 2024, discussing the company's annual report results for 2022. The content includes Q&A about financial performance, risk management, governance, and market strategy. The document is relatively short (2544 characters) and focuses on summarizing the investor relations event rather than providing full financial statements or comprehensive financial data. It is not the annual report itself but a record of an earnings or performance explanation meeting. This fits the category of an Earnings Release (ER) or possibly an Investor Presentation (IP). However, since it is a Q&A session specifically about the annual report results and is called a "业绩说明会" (performance explanation meeting), it aligns best with an Earnings Release (ER) which is the initial announcement of quarterly/periodical financial results with key highlights. Therefore, the document is classified as an Earnings Release (ER). FY 2022
2024-05-12 Chinese
华安证券股份有限公司关于广东驱动力生物科技集团股份有限公司《问询函》有关事项的核查意见
Regulatory Filings
2024-05-12 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.